北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場、検査タイプ別（クラミジア・トラコマティスおよび淋菌（CT/NG）検査、HCV検査、HIV検査、子宮頸がん、結核、細菌性膣炎、ヒトパピローマウイルス（HPV）検査、性器ヘルペス、移植に伴うウイルス合併症など）、検査場所別（店頭検査、自己採取/在宅検査、ポイントオブケア検査など）、技術別（分子、血清学、生物の培養/分離など）、エンドユーザー別（病院、診療所、診断センター、研究所、在宅ケア環境など）、流通チャネル別（オンラインおよびオフライン） - 2030年までの業界動向と予測。
北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場の分析と洞察
女性の性的健康に関する意識の高まりにより、市場の需要が高まっています。より良い健康サービスを求める医療費の増加も、市場の成長に貢献しています。主要な市場プレーヤーは、この重要な時期にさまざまなサービスの立ち上げと承認に重点を置いています。さらに、プロセスと技術の改善された進歩の増加も、女性の性的健康に対する需要の高まりに貢献しています。
市場は、市場プレーヤーの増加と高度なサービスの利用可能性により、予測年度に成長すると予想されています。これに伴い、メーカーは新しいサービスと効率的で正確な性健康検査を開始するための開発活動に取り組んでいます。高度なヘルスケア技術の開発の増加は、市場の成長をさらに後押ししています。ただし、女性の性的健康製品の製造と商品化に対する厳格な規制などの困難が、市場の成長を抑制すると予想されます。
進歩と開発に対する医療費の増加は、市場にチャンスをもたらすと予想されます。ただし、検査のコストが高いため、市場の成長が妨げられる可能性があります。
さまざまな企業が、徐々に市場の成長につながる取り組みを行っています。
例えば、
- 2023年2月、世界有数の医療技術企業であるBDは、米国食品医薬品局（FDA）がThinPrepパップテストと併用するBDオンクラリティHPVアッセイの市場承認を取得したと発表しました。この承認により、同社は製品の強化と新製品の研究を進めることができます。
- 2020年9月、F.ホフマン・ラ・ロシュ社は、2020年4月のFDA承認に続き、米国でElecsys HIV Duo免疫測定法の発売を発表しました。この検査は、HIV p24抗原（ウイルス）と抗HIV抗体（免疫反応によって引き起こされる）を別々に測定することで、急性HIV感染を検出できます。この製品の発売は、同社の製品ポートフォリオの拡大に貢献しました。
Data Bridge Market Research は、北米の女性の性的健康市場は、予測期間中に 9.5% の CAGR で成長し、2030 年までに 28 億 3,439 万米ドルの価値に達すると予測しています。
データブリッジ・マーケット・リサーチは、ヨーロッパの女性の性的健康市場は、予測期間中に8.7%のCAGRで成長し、2030年までに14億8,416万米ドルの価値に達すると予測しています。
データブリッジ・マーケット・リサーチは、アジア太平洋地域の女性の性的健康市場は、予測期間中に年平均成長率10.3%で成長し、2030年までに12億7,782万米ドルに達すると予測しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2015～2020年にカスタマイズ可能) |
|
定量単位 |
収益は百万ドル、価格は米ドル |
|
対象セグメント |
検査の種類 (クラミジア・トラコマティスおよび淋菌 (CT/NG) 検査、HCV 検査、HIV 検査、子宮頸がん、結核、細菌性膣炎、ヒトパピローマウイルス (HPV) 検査、性器ヘルペス、移植に伴うウイルス合併症など)、検査場所 (市販の検査、自己採取/自宅での検査、ポイントオブケア検査など)、技術 (分子、血清学、微生物の培養/分離など)、エンドユーザー (病院、診療所、診断センター、研究所、在宅ケア環境など)、流通チャネル (オンラインおよびオフライン) |
|
対象国 |
米国、カナダ、ドイツ、フランス、英国、中国、日本、オーストラリア |
|
対象となる市場プレーヤー |
Trinity Biotech、BIOMÉRIEUX、Accuquik Test Kits、JOYSBIO (Tianjin) Biotechnology Co., Ltd、Arbor Vita、Randox Laboratories Ltd.、Chembio Diagnostics、Inc.、Cepheid、ELITech Group、Abbott、F. Hoffmann-La Roche Ltd.、Bio-Rad Laboratories、Inc.、Sekisui Diagnostics (SEKISUI Chemical Co. Ltd. の一部門)、Quidel Corporation、BD、OraSure Technologies、Hologic、Inc.、Biomed Diagnostics、DCN DX ブランドなど。 |
北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場の定義
女性の性的健康は、女性の性的健康に関する全体的な幸福感と満足度を指します。女性に影響を与える性疾患には、クラミジア、淋病、ヘルペス、ヒトパピローマウイルス (HPV)、梅毒などの性感染症 (STI)や、膣感染症、尿路感染症 (UTI)、骨盤内炎症性疾患 (PID) 、ホルモンの不均衡などのさまざまな症状が含まれます。女性の性的健康の市場には、臨床検査、分子診断、ポイントオブケア検査、画像技術、特殊な医療機器など、さまざまな診断ツールと診断方法が存在します。
北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 性感染症の発生率増加
性感染症 (STD) は、世界的に深刻な公衆衛生上の懸念事項であり、さまざまな場所で蔓延しています。STD の蔓延の増加は、女性の性的健康の市場に重大な影響を及ぼしています。これは、性的健康と幸福を高めるための商品やサービスの開発と拡大に大きく影響します。不妊、子宮頸がん、HIV に対する感受性の増加は、STD の長期的な影響と、それがもたらす直接的な健康被害のほんの一部です。世界中の女性の性的福祉を促進するには、STD の増加率に対処する必要があります。
以下は、北米、ヨーロッパ、アジア太平洋地域で増加している STD 蔓延のいくつかのケースと事例であり、それが女性の性的健康の市場にどのような影響を与えているかを明らかにしています。
拘束
- スティグマと社会的タブーが課題
女性の性的健康は、北米、ヨーロッパ、アジア太平洋地域では非難され、社会的にタブー視されており、深刻な問題を引き起こしています。こうした社会的な態度や信念により、女性は性的健康に関するサービスや製品にアクセスしたり、探し出そうとする際に障害に遭遇します。
北米では、性に関する社会的偏見やタブーにより、女性の性的健康について公に取り上げたり話し合ったりすることが難しい場合があります。この偏見は、社会的または宗教的な期待から生じる可能性があり、判断されることへの罪悪感や不安を引き起こす可能性があります。このような態度により、女性は性的健康に関する情報、教育、医療サービスを求めることを躊躇する可能性があります。
ヨーロッパでは、タブーや社会的羞恥心により、人々が性的な健康について率直に話したりサポートを受けたりすることが妨げられている可能性があります。文化的、宗教的、保守的な力が、女性の性的な健康に関する偏見を永続させている可能性があります。この偏見により、女性は性的な健康の治療を求める可能性が低くなり、自分の体や性的ニーズについて知識に基づいた選択を行うことが難しくなる可能性があります。
アジア太平洋地域では、文化的、社会的基準が強く根付いているため、女性の性的健康に関する偏見やタブーが頻繁に生じています。家父長制の構造、保守的な考え方、包括的な性教育へのアクセスの制限により、偏見が根強く残ります。女性は、社会的偏見、親やコミュニティの非難、批判を懸念して、性に関する健康教育、検査、ケアを受けることをためらうことがあります。
機会
-
性的健康に関する製品の承認と発売の増加
製品の承認と発売の増加は、女性の性的健康市場の成長にとって大きなチャンスとなります。承認された製品が利用可能になることで、消費者の信頼が高まり、製品の安全性、有効性、品質が保証されます。また、治療の選択肢が広がり、性機能障害などの症状に対する革新的なソリューションが提供されます。承認された製品へのアクセスと入手性が向上することで、市場はより広範な消費者層にリーチし、これまで満たされなかったニーズに対応できます。さらに、新製品の承認と発売は研究とイノベーションを刺激し、テクノロジーの限界を押し広げ、市場の拡大を促進します。
チャレンジ
- 標準化、ガイドライン、倫理的配慮の欠如
女性の性的健康市場は、標準化と倫理的配慮の欠如を特徴とする重大な問題に直面しています。このような堅牢なガイドラインと規制の欠如は、消費者と業界にとって大きな課題となっています。主な懸念事項の 1 つは、市場で入手可能な製品の品質に一貫性がないことです。さらに、標準化されたテスト プロトコルがないため、これらの製品の科学的検証が妨げられ、証拠に基づく知識が限られ、情報に基づいた意思決定が妨げられています。
一貫性のない製品品質: 標準化された規制がないため、市場に出回っている女性向け性的健康製品の品質には大きなばらつきがあります。この一貫性の欠如により、消費者の安全性と満足度が損なわれ、健康への悪影響や効果のない結果につながる可能性があります。
最近の動向
- 2023年3月、トリニティ・バイオテック社は、ケニア保健省による新しいHIV迅速検査アルゴリズムの採用発表を歓迎した。この新しいアルゴリズムにより、トリニティ・バイオテック社のTrinScreen HIVがスクリーニング検査（A1 = 世界保健機関（WHO）ガイドラインに基づくスクリーニング検査）として確立される。
- 2022年5月、Quidel Corporation（「QuidelOrtho」）は、Quidel Corporation（「Quidel」）とOrtho Clinical Diagnostics Holdings plc（「Ortho」）の統合取引の完了を発表しました。これにより、大手体外診断会社であるQuidelOrthoが誕生しました。新会社はカリフォルニア州サンディエゴに本社を置きます。この合併は、同社の臨床診断分野での事業拡大にも役立つでしょう。
北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場の範囲
北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場は、テストの種類、テスト場所、テクノロジー、エンドユーザー、流通チャネルなど、5 つの主要なセグメントに分割されています。セグメント間の成長は、ニッチな成長分野と市場にアプローチするための戦略を分析し、コア アプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
北米、ヨーロッパ、アジア太平洋地域の女性向け性的ウェルネス市場（検査タイプ別）
- クラミジア・トラコマティスおよび淋菌（CT/NG）検査
- HCV検査
- HIV検査
- 子宮頸がん
- 結核
- 細菌性膣炎
- ヒトパピローマウイルス（HPV）検査
- 性器ヘルペス
- 移植に伴うウイルス性合併症
- その他
検査の種類に基づいて、市場はクラミジア・トラコマティスおよび淋菌（CT / NG）検査、HCV検査、HIV検査、子宮頸がん、結核、細菌性膣炎、ヒトパピローマウイルス（HPV）検査、性器ヘルペス、移植に伴うウイルス合併症などに分類されます。
北米、ヨーロッパ、アジア太平洋地域の女性向け性的ウェルネス市場（テスト場所別）
- 市販の検査
- 自己採取/自宅での検査
- ポイントオブケア検査
- その他
検査場所に基づいて、市場は店頭検査、自己採取/在宅検査、ポイントオブケア検査、その他に分類されます。
北米、ヨーロッパ、アジア太平洋地域の女性の性的ウェルネス市場（技術別）
- 分子
- 血清学
- 生物の培養/分離
- その他
技術に基づいて、市場は分子、血清学、生物の培養/分離、その他に分類されます。
北米、ヨーロッパ、アジア太平洋地域の女性向け性的ウェルネス市場（エンドユーザー別）
- 病院
- クリニック
- 診断センター
- 研究室
- ホームケア設定
- その他
エンドユーザーに基づいて、市場は病院、診療所、診断センター、研究所、在宅ケア環境、その他に分類されます。
北米、ヨーロッパ、アジア太平洋地域の女性向け性的ウェルネス市場（流通チャネル別）
- オンライン
- オフライン
流通チャネルに基づいて、市場はオンラインとオフラインに分割されます。
北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場の地域分析/洞察
市場は、テストの種類、テストの場所、テクノロジー、エンド ユーザー、流通チャネルの 5 つの主要なセグメントに分類されます。
この市場レポートで取り上げられている国は、米国、カナダ、ドイツ、フランス、英国、中国、日本、オーストラリアです。
北米地域ではHIVやHCVなどの性関連疾患の蔓延率が高いため、米国が市場を独占すると予想されています。医療費の増加により、ドイツがヨーロッパ地域で市場を独占すると予想されています。性健康に対する意識の高まりにより、中国がアジア太平洋地域で市場を独占すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
競争環境と北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場シェア分析
北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と幅、アプリケーションの優位性、製品タイプのライフライン曲線などがあります。提供されている上記のデータ ポイントは、北米、ヨーロッパ、アジア太平洋地域の女性の性的健康市場への会社の重点にのみ関連しています。
市場で活動している主要な市場プレーヤーには、Trinity Biotech、BIOMÉRIEUX、Accuquik Test Kits、JOYSBIO (Tianjin) Biotechnology Co., Ltd、Arbor Vita、Randox Laboratories Ltd.、Chembio Diagnostics、Inc.、Cepheid、ELITech Group、Abbott、F. Hoffmann-La Roche Ltd.、Bio-Rad Laboratories、Inc.、Sekisui Diagnostics (SEKISUI Chemical Co. Ltd. の一部門)、Quidel Corporation、BD、OraSure Technologies、Hologic、Inc.、Biomed Diagnostics、DCN DX Brand などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TEST TYPE LIFELINE CURVE (NORTH AMERCA)
2.8 TEST TYPE LIFELINE CURVE (EUROPE)
2.9 TEST TYPE LIFELINE CURVE (ASIA-PACIFIC)
2.1 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.11 DBMR MARKET POSITION GRID
2.12 MARKET TESTING TYPE COVERAGE GRID
2.13 VENDOR SHARE ANALYSIS
2.14 SECONDARY SOURCES
2.15 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
4.3 KEY STRATEGIC INITIATIVES
4.4 TREND ANALYSIS
4.4.1 TV (TRICHOMONAS VAGINALIS)
4.4.2 M. GEN (MYCOPLASMA GENITALIUM)
4.4.3 HIV
4.4.4 HBV, HCV (HEPATITIS B & C)
4.4.5 CMV (CYTOMEGALOVIRUS)
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES
5.1.2 GROWING AWARENESS ABOUT STDS
5.1.3 RISE IN THE PREFERENCE FOR HOME CARE TESTING IN WOMEN SEXUAL WELLNESS
5.2 RESTRAINTS
5.2.1 HIGH COST ASSOCIATED WITH TESTING
5.2.2 STIGMA AND SOCIAL TABOOS A CHALLENGE
5.3 OPPORTUNITIES
5.3.1 INCREASING PRODUCT APPROVALS AND PRODUCT LAUNCHES FOR SEXUAL WELLNESS
5.3.2 THE INCREASING PRODUCTS APPROVALS AND THEIR LAUNCHES
5.4 CHALLENGES
5.4.1 LACK OF STANDARDIZATION, GUIDELINES, AND ETHICAL CONSIDERATIONS
5.4.2 LACK OF COMPREHENSIVE EDUCATION
6 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE
6.1 OVERVIEW
6.2 HUMAN PAPILLOMAVIRUS (HPV) TESTING
6.3 GENITAL HERPES
6.4 CERVICAL CANCER
6.4.1 PAP SMEAR TEST
6.4.2 OTHER DIAGNOSTIC TESTS
6.5 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
6.5.1 RAPID TEST KITS
6.5.2 SEROLOGY TESTS
6.5.3 DIRECT FLUORESCENT ANTIBODY TEST
6.5.4 OTHER TEST TYPES
6.6 HIV TEST
6.6.1 ANTIBODY TEST
6.6.2 NUCLEIC ACID TESTS (NATS)
6.6.3 OTHERS
6.7 HCV TEST
6.7.1 HCV ANTIBODY TESTING
6.7.2 HCV VIRAL LOAD TESTING
6.7.3 HCV GENOTYPING TESTING
6.7.4 BACTERIAL VAGINOSIS
6.8 TUBERCULOSIS
6.8.1 CULTURE BASED DIAGNOSIS
6.8.2 SPUTUM SPEAR MICROSCOPY
6.8.3 RAPID MOLECULAR DIAGNOSTICS
6.9 VIRAL COMPLICATIONS WITH TRANSPLANT
6.1 OTHERS
7 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION
7.1 OVERVIEW
7.2 POINT-OF-CARE TESTING
7.2.1 HUMAN PAPILLOMAVIRUS (HPV) TESTING
7.2.2 GENITAL HERPES
7.2.3 CERVICAL CANCER
7.2.4 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
7.2.5 HIV TEST
7.2.6 HCV TEST
7.2.7 BACTERIAL VAGINOSIS
7.2.8 TUBERCULOSIS
7.2.9 VIRAL COMPLICATIONS WITH TRANSPLANT
7.2.10 OTHERS
7.3 SELF-COLLECTION/AT HOME TESTING
7.3.1 GENITAL HERPES
7.3.2 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
7.3.3 HUMAN PAPILLOMAVIRUS (HPV) TESTING
7.3.4 HIV TEST
7.3.5 HCV TEST
7.3.6 BACTERIAL VAGINOSIS
7.3.7 CERVICAL CANCER
7.3.8 TUBERCULOSIS
7.3.9 VIRAL COMPLICATIONS WITH TRANSPLANT
7.3.10 OTHERS
7.4 OVER-THE-COUNTER TESTING
7.4.1 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST
7.4.2 HCV TEST
7.4.3 GENITAL HERPES
7.4.4 HUMAN PAPILLOMAVIRUS (HPV) TESTING
7.4.5 HIV TEST
7.4.6 BACTERIAL VAGINOSIS
7.4.7 CERVICAL CANCER
7.4.8 TUBERCULOSIS
7.4.9 VIRAL COMPLICATIONS WITH TRANSPLANT
7.4.10 OTHERS
7.5 OTHERS
8 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 SEROLOGY
8.3 MOLECULAR
8.4 CULTURE/ISOLATION OF ORGANISM
8.5 OTHERS
9 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 PUBLIC
9.4 PRIVATE
9.5 CLINICS
9.5.1 WOMEN HEALTHCARE CLINICS
9.5.2 GYNECOLOGY CLINICS
9.5.3 OTHERS
9.6 DIAGNOSTIC CENTERS
9.7 LABORATORIES
9.8 HOME CARE SETTING
9.9 OTHERS
10 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 OFFLINE
10.3 ONLINE
11 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET : BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA.
11.2 EUROPE
11.2.1 GERMANY
11.2.2 U.K.
11.2.3 FRANCE
11.3 ASIA-PACIFIC
11.3.1 HINA
11.3.2 JAPAN
11.3.3 AUSTRALIA
12 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.2 COMPANY SHARE ANALYSIS: EUROPE
12.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 NORTH AMERICA, EUROPE, ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET
14.1 HOLOGIC, INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 CEPHEID. (SUBSIDARY OF DANAHER)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 F. HOFFMANN-LA ROCHE LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 ABBOTT
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 BIO-RAD LABORATORIES, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ACCUQUIK TEST KITS. (ADVACARE PHARMA USA)
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 ARBOR VITA CORPORATION
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENT
14.8 BD.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.9 BIOMED DIAGNOSTICS, A DCN DX BRAND
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 BIOMÉRIEUX (2022)
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 CHEMBIO DIAGNOSTICS, INC. (2022)
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 ELITECH GROUP
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 ORASURE TECHNOLOGIES
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 QUIDEL CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 RANDOX LABORATORIES LTD.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SEKISUI DIAGNOSTICS (A PART OF SEKISUI CHEMICAL CO. LTD.)
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 TRINITY BIOTECH (2022)
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表のリスト
TABLE 1 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 5 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 6 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 7 NORTH AMERICA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA-PACIFIC CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 12 ASIA-PACIFIC CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 14 EUROPE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 ASIA-PACIFIC HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 17 EUROPE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 18 ASIA-PACIFIC HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 26 EUROPE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 27 ASIA-PACIFIC POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 29 EUROPE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 32 EUROPE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 33 ASIA-PACIFIC OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 35 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 38 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 EUROPE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 42 ASIA-PACIFIC HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 44 EUROPE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 45 ASIA-PACIFIC CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 47 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 52 NORTH AMERICA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 66 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 68 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 69 U.S. CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.S. CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 U.S. HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.S. TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 75 U.S. POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.S. SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.S. OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 U.S. WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 79 U.S. WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 80 U.S. HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 U.S. CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 U.S. WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 85 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 86 CANADA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 CANADA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 CANADA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 89 CANADA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 90 CANADA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 92 CANADA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 CANADA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 CANADA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 CANADA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 96 CANADA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 CANADA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 98 CANADA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 99 CANADA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 100 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 101 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 103 EUROPE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 EUROPE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 EUROPE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 106 EUROPE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 107 EUROPE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 109 EUROPE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 110 EUROPE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 EUROPE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 113 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 EUROPE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 EUROPE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 116 EUROPE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 117 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 118 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 119 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 120 GERMANY CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 GERMANY CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 122 GERMANY HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 123 GERMANY HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 124 GERMANY TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 125 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 126 GERMANY POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 GERMANY SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 GERMANY OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 130 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 131 GERMANY HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 132 GERMANY CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 133 GERMANY WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 134 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 136 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 137 U.K. CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 U.K. CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 139 U.K. HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 140 U.K. HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 141 U.K. TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 142 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 143 U.K. POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 U.K. SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 U.K. OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 U.K. WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 147 U.K. WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 U.K. HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 149 U.K. CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 150 U.K. WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 151 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 152 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 153 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 154 FRANCE CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 155 FRANCE CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 156 FRANCE HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 157 FRANCE HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 158 FRANCE TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 160 FRANCE POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 FRANCE SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 FRANCE OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 164 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 165 FRANCE HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 166 FRANCE CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 167 FRANCE WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 168 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 169 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 170 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 171 ASIA-PACIFIC CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 172 ASIA-PACIFIC CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 173 ASIA-PACIFIC HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 174 ASIA-PACIFIC HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 175 ASIA-PACIFIC TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 176 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 177 ASIA-PACIFIC POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 ASIA-PACIFIC SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 179 ASIA-PACIFIC OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 180 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 181 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 182 ASIA-PACIFIC HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 ASIA-PACIFIC CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 184 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 185 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 187 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 188 CHINA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 189 CHINA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 190 CHINA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 191 CHINA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 192 CHINA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 193 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 194 CHINA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 CHINA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 196 CHINA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 197 CHINA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 198 CHINA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 199 CHINA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 200 CHINA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 201 CHINA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 202 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 203 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 204 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 205 JAPAN CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 206 JAPAN CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 207 JAPAN HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 JAPAN HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 209 JAPAN TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 210 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 211 JAPAN POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 212 JAPAN SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 213 JAPAN OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 214 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 215 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 216 JAPAN HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 JAPAN CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 218 JAPAN WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 219 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 220 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 221 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (NUMBER OF TESTS)
TABLE 222 AUSTRALIA CERVICAL CANCER IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 223 AUSTRALIA CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 AUSTRALIA HIV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 225 AUSTRALIA HCV TEST IN WOMEN SEXUAL WELLNESS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 226 AUSTRALIA TUBERCULOSIS IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TEST LOCATION, 2021-2030 (USD MILLION)
TABLE 228 AUSTRALIA POINT-OF-CARE TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 229 AUSTRALIA SELF-COLLECTION/AT HOME TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 230 AUSTRALIA OVER THE COUNTER TESTING IN WOMEN SEXUAL WELLNESS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 231 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 232 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 233 AUSTRALIA HOSPITALS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 234 AUSTRALIA CLINICS IN WOMEN SEXUAL WELLNESS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 235 AUSTRALIA WOMEN SEXUAL WELLNESS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 6 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 7 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 8 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 EUROPE WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID
FIGURE 11 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: DBMR MARKET POSITION GRID
FIGURE 12 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 13 EUROPE WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 14 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 15 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: VENDOR SHARE ANALYSIS
FIGURE 16 NORTH AMERICA, EUROPE AND ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SEGMENTATION
FIGURE 17 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD
FIGURE 18 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE EUROPE WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD
FIGURE 19 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES ARE EXPECTED TO DRIVE THE ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET IN THE FORECAST PERIOD
FIGURE 20 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030
FIGURE 21 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030
FIGURE 22 THE HUMAN PAPILLOMAVIRUS (HPV) TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET IN 2023 & 2030
FIGURE 23 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NA, EUROPE AND APAC WOMEN SEXUAL WELLNESS MARKET
FIGURE 24 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022
FIGURE 25 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 26 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 27 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 28 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022
FIGURE 29 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 30 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 31 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2022
FIGURE 33 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 34 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 35 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022
FIGURE 37 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)
FIGURE 38 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)
FIGURE 39 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE
FIGURE 40 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022
FIGURE 41 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)
FIGURE 42 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)
FIGURE 43 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2022
FIGURE 45 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, 2023-2030 (USD MILLION)
FIGURE 46 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, CAGR (2023-2030)
FIGURE 47 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TEST LOCATION, LIFELINE CURVE
FIGURE 48 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022
FIGURE 49 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 50 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 51 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 52 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022
FIGURE 53 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 54 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 55 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 56 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2022
FIGURE 57 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 58 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 59 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 60 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022
FIGURE 61 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 62 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 63 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE
FIGURE 64 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022
FIGURE 65 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 66 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 67 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE
FIGURE 68 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2022
FIGURE 69 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 70 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 71 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY END USER, LIFELINE CURVE
FIGURE 72 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 73 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 74 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 75 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 76 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 77 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 78 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 79 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 80 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 81 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 82 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 83 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 84 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)
FIGURE 85 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)
FIGURE 86 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 87 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 88 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)
FIGURE 89 EUROPE WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)
FIGURE 90 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)
FIGURE 91 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 92 EUROPE WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 93 EUROPE WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)
FIGURE 94 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: SNAPSHOT (2022)
FIGURE 95 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022)
FIGURE 96 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 97 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 98 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: TEST TYPE (2023-2030)
FIGURE 99 NORTH AMERICA WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)
FIGURE 100 EUROPE WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)
FIGURE 101 ASIA-PACIFIC WOMEN SEXUAL WELLNESS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
